Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 1.00 |
| ▸ | CTSB | P07858 | 6/20 | 1.00 |
| ▸ | CTSL | P07711 | 5/20 | 1.00 |
| ▸ | USP30 | Q70CQ3 | 12/20 | 0.62 |
| ▸ | UCHL1 | P09936 | 6/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | CTSC | P53634 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858391 | 0.89 | CTSK (1.00) | CTSKCTSBCTSLUSP30UCHL1 | |
| SCHEMBL14819973 | 0.81 | ALDH1A1 (0.68) | CTSKCTSBCTSLALDH1A1PKM | |
| SCHEMBL13644758 | 0.77 | USP30 (1.00) | CTSKCTSBCTSLUSP30UCHL1 | |
| SCHEMBL20576333 | 0.77 | USP30 (1.00) | CTSKCTSBCTSLUSP30UCHL1 | |
| SCHEMBL6856730 | 0.77 | USP30 (1.00) | CTSKCTSBCTSLUSP30UCHL1 | |
| SCHEMBL2470122 | 0.76 | GBA1 (1.00) | CTSKCTSBCTSLALDH1A1PKM | |
| SCHEMBL7011360 | 0.76 | CTSK (1.00) | CTSKCTSBCTSLUSP30UCHL1 | |
| SCHEMBL14805894 | 0.76 | CTSL (0.62) | CTSKCTSBCTSLALDH1A1PKM | |
| SCHEMBL3826835 | 0.76 | CTSL (0.67) | CTSKCTSBCTSLUSP30CTSS | |
| SCHEMBL18987033 | 0.76 | USP30 (1.00) | CTSKCTSBCTSLUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835727-B2 | Bone disorders; osteoporosis; rheumatic diseases | MERCK FROSST CANADA & CO. (CA) | 2004-12-28 | — | — | US | claimed |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | claimed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | claimed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | claimed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | claimed |
| US-6835727-B2 | Bone disorders; osteoporosis; rheumatic diseases | MERCK FROSST CANADA & CO. (CA) | 2004-12-28 | — | — | US | disclosed |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | disclosed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | disclosed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | CTSK, CTSZ, CTSE | CTSK 1/4885CTSB 5/4885CTSL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.